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Background:  Risk for congestive heart failure (CHF) is increased significantly in diabetes, independent of hypertension and atherosclerosis. While 
vasodilators improve CHF outcomes, clinical benefit is greater with renin-angiotensin system (RAS) inhibitors, such as losartan and enalapril, than 
with hydralazine. We used the female, BTBR leptin-deficient (ob/ob) mouse model of diabetic cardiomyopathy (in which significant diabetes, cardiac 
hypertrophy, fibrosis, and myocardial macrophage accumulation develop by 16 weeks of age) to study the effects of treatment with hydralazine, 
losartan and enalapril on established cardiomyopathy.
Methods:  At age 18 weeks, female BTBR ob/ob mice were randomized to four groups: no treatment, hydralazine (50 mg/kg/d), losartan (25 mg/
kg/d), or enalapril (30 mg/kg/d). Mice were sacrificed at age 24 weeks. LV myocardial cross-sectional area, myocyte size, fibrosis, and macrophage 
content were determined for 4-7 mice/group. Results were analyzed by one-way ANOVA, with Dunnett’s correction for multiple comparisons.
Results:  While all three drugs effected similar decreases in systolic and diastolic blood pressures as compared to controls, the extent of 
myocardial fibrosis was similar across all four groups. As compared to the control group, the hydralazine group had significant increases in heart 
weight (+20%, P<0.05), LV myocardial cross-sectional area (+32%, P<0.01) and myocyte size (+59%, P<0.05); these parameters did not differ 
from control for the losartan or enalapril groups. In contrast, myocardial macrophage content was unchanged with hydralazine, but decreased non-
significantly with losartan (-52%, P<NS) and significantly with enalapril (-93%, P<0.05).
Conclusion: Six weeks treatment of established diabetic cardiomyopathy with hydralazine resulted in significant increases in cardiac hypertrophy 
and myocyte size. In contrast, enalapril significantly decreased myocardial inflammation. These divergent vasodilator effects may have important 
clinical implications, and the molecular mechanisms underlying these findings warrant further investigation.
